Abstract
Abstract only
e19035
Background: EGFR mutation is an important therapeutic marker for the management of NSCLC with known ethnic variations. Our study aims at determining the prevalence of the mutation in the Middle East and its correlation with demographic and clinical features. Methods: A multisite retrospective study was conducted including institutions from Saudi Arabia, UAE, Qatar and Egypt. All consecutive patients (pts) with NSCLC tested for EGFRMUT were eligible. Data were obtained on demographic and disease characteristics, and EGFR test results. Institutional Review Board approval was obtained from all participating sites. Results: Data on 201 patients were obtained. Median age was 61 years (51 - 69), 140 (69.65%) were males and 174 pts were Arab (86.57%) Tumor histology subtypes were adenocarcinoma in 175 patients (87.07%), squamous cell carcinoma in 15 pts (7.46%) and others in 11 pts (5.48%). EGFRMUT was detected in 66 pts, with (36.50%) prevalence in adenocarcinoma. No squamous cell carcinoma harbored EGFRMUT. The most frequent abnormality detected was in exon 19 in 39 pts (57.36%), abnormalities in exon 21 in 22 pts (32.35%) and in exon 18 in 7 pts (10.29%). Two pts had dual mutations on exons 19 and 21. Univariate and multivariate analyses revealed significant predictors for having EGFRMUT to be: female gender (42.42 % vs. 27.7% in males, p= 0.0096), non-smoking status (81.82% vs. 16.21% in smokers, p=0.0001) and adenocarcinoma subtypes (36.25 % vs. 15.38% in others, p=0.035). There was no difference between Arabs and non-Arabs. Conclusions: This is the first study from our region to report the prevalence of EGFRMUT in ME population which seems to be similar to Far East population with similar clinical predictors. Studies about the impact of targeted therapy in our patient’s population are underway.